Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc. is a biotech company specializing in the development of oral drug delivery systems for diabetes and other conditions. Its flagship product aims to provide a non-invasive alternative to injectable medications by utilizing innovative oral protein delivery technology. The company focuses on advancing treatments for diabetes and other chronic diseases through its proprietary oral insulin and peptide formulations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 26, 2026 | $0.25 | 2026-01-16 | 2026-01-16 |
Dividends Summary
- Consistent Payer: Oramed Pharmaceuticals Inc. has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held ORMP shares during this period received a total of $0.25 per share in dividend income.
- Latest Payout: The most recent dividend of $0.25/share was paid 173 days ago, on January 26, 2026.
Company News
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced it will be added to the Russell 2000® and Russell 3000® indexes following the 2026 semi-annual reconstitution, effective June 29, 2026. The inclusion is based on the company's market capitalization ranking as of April 30, 2026, and will provide automatic inclusion in appropriate growth and va...
Lifeward Ltd. announced shareholder approval for a strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology platform. The deal provides Lifeward with up to $47 million in capital while allowing the company to diversify from its core medical technology business into biotechnology. Oramed will manage a...
Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, closing out option agreement obligations and bringing total returns to $118 million on its original $99.5 million investment. The company's board approved a $0.25 per share cash dividend (~$10.5 million aggregate) to be paid on January 26, 2026. Oramed retains $39 millio...
Oramed Pharmaceuticals announced a Rights Plan to protect against hostile takeovers, distributing one common stock purchase right per outstanding share, with rights becoming exercisable if a person/group acquires 15% or more of outstanding stock.
Oramed Pharmaceuticals announced a joint venture with Hefei Tianhui Biotech to accelerate the development and commercialization of its oral insulin and other oral drug delivery technologies. The new company, OraTech Pharmaceuticals, will receive significant financial backing and leverage HTIT's manufacturing capabilities.
